
Marina G M Castor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9158635/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment with a Novel Chemokine-Binding Protein or Eosinophil Lineage-Ablation Protects Mice from Experimental Colitis. American Journal of Pathology, 2009, 175, 2382-2391.	1.9	85
2	Encapsulated mesenchymal stem cells for in vivo immunomodulation. Leukemia, 2013, 27, 500-503.	3.3	67
3	The CCL3/Macrophage Inflammatory Protein-1α–Binding Protein Evasin-1 Protects from Graft-versus-Host Disease but Does Not Modify Graft-versus-Leukemia in Mice. Journal of Immunology, 2010, 184, 2646-2654.	0.4	51
4	Control of murine Ly6Chigh monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6. Blood, 2012, 119, 5250-5260.	0.6	33
5	The Role of Chemokines in Mediating Graft Versus Host Disease: Opportunities for Novel Therapeutics. Frontiers in Pharmacology, 2012, 3, 23.	1.6	30
6	PI3Kγ controls leukocyte recruitment, tissue injury, and lethality in a model of graft-versus-host disease in mice. Journal of Leukocyte Biology, 2011, 89, 955-964.	1.5	23
7	Serotonin induces peripheral mechanical antihyperalgesic effects in mice. European Journal of Pharmacology, 2015, 767, 94-97.	1.7	19
8	The Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine. Journal of Pain, 2018, 19, 487-495.	0.7	19
9	Platelet-activating factor receptor plays a role in the pathogenesis of graft-versus-host disease by regulating leukocyte recruitment, tissue injury, and lethality. Journal of Leukocyte Biology, 2012, 91, 629-639.	1.5	18
10	NSAIDs induce peripheral antinociception by interaction with the adrenergic system. Life Sciences, 2015, 130, 7-11.	2.0	17
11	κ-Opioid receptor participates of NSAIDs peripheral antinociception. Neuroscience Letters, 2016, 622, 6-9.	1.0	17
12	Inhibition of 5-lipoxygenase alleviates graft-versus-host disease. Journal of Experimental Medicine, 2017, 214, 3399-3415.	4.2	16
13	Serotonin induces peripheral antinociception via the opioidergic system. Biomedicine and Pharmacotherapy, 2018, 97, 1434-1437.	2.5	16
14	Lithothamnion muelleri Controls Inflammatory Responses, Target Organ Injury and Lethality Associated with Graft-versus-Host Disease in Mice. Marine Drugs, 2013, 11, 2595-2615.	2.2	12
15	Angiotensin-(1–7) through Mas receptor activation induces peripheral antinociception by interaction with adrenoreceptors. Peptides, 2015, 69, 80-85.	1.2	10
16	Cannabidiol Enhances Intestinal Cannabinoid Receptor Type 2 Receptor Expression and Activation Increasing Regulatory T Cells and Reduces Murine Acute Graft-versus-Host Disease without Interfering with the Graft-versus-Leukemia Response. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 273-283.	1.3	10
17	Nanocomposite Treatment Reduces Disease and Lethality in a Murine Model of Acute Graft-versus-Host Disease and Preserves Anti-Tumor Effects. PLoS ONE, 2015, 10, e0123004.	1.1	10
18	Evidence for the involvement of opioid and cannabinoid systems in the peripheral antinociception mediated by resveratrol. Toxicology and Applied Pharmacology, 2019, 369, 30-38.	1.3	9

MARINA G M CASTOR

#	Article	IF	CITATIONS
19	Noradrenaline induces peripheral antinociception by endogenous opioid release. Pharmacological Reports, 2018, 70, 784-788.	1.5	8
20	Treatment with Apocynin Limits the Development of Acute Graft-versus-Host Disease in Mice. Journal of Immunology Research, 2019, 2019, 1-14.	0.9	6
21	α2-Adrenoceptor agonist induces peripheral antinociception via the endocannabinoid system. Pharmacological Reports, 2020, 72, 96-103.	1.5	2
22	Natural Diterpenes from Coffee, Cafestol, and Kahweol Induce Peripheral Antinoceception by Adrenergic System Interaction. Planta Medica, 2016, 82, 106-112.	0.7	1
23	Kahweol, a natural diterpene from coffee, induces peripheral antinociception by endocannabinoid system activation. Brazilian Journal of Medical and Biological Research, 2021, 54, e11071.	0.7	1
24	Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies. Intestinal Research, 2022, 20, 392-417.	1.0	1